*( Page 1 of 1 )*
<---*(
2019 Novel Coronavirus (2019-nCoV) Situation Summary)*--->
https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html <---*(
Learn More About the Symptoms Associated with 2019-nCoV)*--->
https://www.cdc.gov/coronavirus/2019-ncov/about/symptoms.html <---*(
2019 Novel Coronavirus (2019-nCoV) CASES & MAP in the U.S.)*--->
https://www.cdc.gov/coronavirus/2019-ncov/cases-in-us.html <---*(
Confirmed 2019-nCoV Cases Globally Global Map)*--->
https://www.cdc.gov/coronavirus/2019-ncov/locations-confirmed-cases.htmlUpdated June 5, 2020Key Updates for
Week 22, Ending
May 30, 2020Nationally, levels of influenza-like illness (ILI) and COVID-19-like illness (CLI) and the percentage of specimens testing positive for SARS-CoV-2, the virus that causes COVID-19, continue to decline or remain stable at low levels. Mortality attributed to COVID-19 also decreased compared to last week but remains elevated above baseline and may increase as additional death certificates are processed.
VirusPublic Health, Commercial and Clinical LaboratoriesThe national percentage of respiratory specimens testing positive for SARS-CoV-2 at public health, clinical and commercial laboratories decreased from week 21 to week 22; however, percent positivity increased slightly in four regions. National percentages by type of laboratory:
*
Public health laboratories –
decreased 6.8% during week 21 to 6.0% during week 22
*
Clinical laboratories –
decreased with 6.0% during week 21 and 5.9% during week 22
*
Commercial laboratories –
decreased from 6.5% during week 21 to 5.9% during week 22
Outpatient and Emergency Department VisitsOutpatient Influenza-Like Illness Network (ILINet) and National Syndromic Surveillance Program (
NSSP)
Two surveillance indicators are being used to track outpatient or emergency department (ED) visits for illness with symptoms compatible with COVID-19.
* Nationally, the percentages of visits for ILI and CLI decreased or remained stable at low levels, compared to last week. Levels of
ILI are below baseline nationally for the seventh week and in all 10 surveillance regions for the past five to eight weeks.
Recent changes in health care seeking behavior, including increasing use of telemedicine, recommendations to limit emergency department (ED) visits to severe illnesses, and increased practice of social distancing, are likely affecting data reported from both networks, making it difficult to draw conclusions at this time. Tracking these systems moving forward will give additional insight into illness related to COVID-19.
Severe DiseaseHospitalizationsCumulative COVID-19-associated hospitalization rates since March 1, 2020, are updated weekly. The overall cumulative COVID-19 hospitalization rate is 82.0 per 100,000, with the highest rates in people aged 65 years and older (254.7 per 100,000) and 50-64 years (126.2 per 100,000).
MortalityBased on death certificate data, the percentage of deaths attributed to pneumonia, influenza or COVID-19 (PIC) decreased from 13.7% during week 21 to 8.4% during week 22 but remained above baseline. This is the sixth week of a declining percentage of deaths due to PIC, but this percentage may change as more death certificates are processed, particularly for recent weeks.
All data above are preliminary and may change as more reports are received.
A description of the surveillance systems summarized in COVIDView, including methodology and detailed descriptions of each data component, is available on the surveillance methods page.
https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/purpose-methods.htmlKey Points * Nationally, the percentages of laboratory specimens testing positive for SARS-CoV-2 with a molecular assay decreased compared
to last week; however, there are two developments in particular worth noting:
* The percent positivity increased in four HHS surveillance regions: Region 4 (the southeast), Region 6 (the south central,
Region 9 (the west coast) and Region 10 (the Pacific northwest).
* While the number of specimens from children <18 years of age tested is low (<5% of all specimens tested in public health
and commercial laboratories), the percentage testing positive for SARS-CoV-2 in this age group continued to either trend
upward or remain relatively stable while other age groups have seen consistent declines in percent positivity in recent weeks.
* Nationally, visits to outpatient providers and emergency departments (EDs) for illnesses with symptoms consistent with COVID-19
continued to decline or remain stable at low levels. Outpatient ILI visits are below baseline nationally and in all regions of the
country.
* The decrease in the percentage of people presenting for care with ILI and CLI may be due to a decline in COVID-19 illness,
which could be in part a result of widespread adoption of social distancing, in addition to decreases in healthcare seeking
behavior.
* There has been very little influenza virus activity in recent weeks.
* The overall cumulative COVID-19 associated hospitalization rate is 82.0 per 100,000, with the highest rates in people 65 years of
age and older (254.7 per 100,000) followed by people 50-64 years (126.2 per 100,000). Hospitalization rates are cumulative and
will increase as the COVID-19 pandemic continues.
* Non-Hispanic American Indian or Alaska Native persons have a rate approximately 5 times that of non-Hispanic White persons,
non-Hispanic Black persons have a rate approximately 4.5 times that of non-Hispanic White persons, while Hispanics or Latino
persons have a rate approximately 3.5 times that of non-Hispanic White persons.
* Cumulative hospitalization rates for COVID-19 in adults (18-64 years) at this time are higher than cumulative end-of-season
hospitalization rates for influenza over each of the past 5 influenza seasons.
* For people 65 years and older, current cumulative COVID-19 hospitalization rates are within ranges of cumulative influenza
hospitalization rates observed at comparable time points* during recent influenza seasons.
* For children (0-17 years), cumulative COVID-19 hospitalization rates are much lower than cumulative influenza hospitalization
rates at comparable time points* during recent influenza seasons.
* Based on death certificate data, the percentage of deaths attributed to pneumonia, influenza or COVID-19 (PIC) decreased from
13.7% during week 21 to 8.4% during week 22. This is the sixth week during which a declining percentage of deaths due to PIC
has been recorded; however, the percentage remains above the epidemic threshold, and is now similar to what has been observed
at the peak of some influenza seasons. The percentage may change as additional death certificates for deaths during recent weeks
are processed.
*Number of weeks since 10% of specimens tested positive for SARS-CoV-2 and influenza, respectively.
U.S. Virologic SurveillanceThe number of specimens tested for SARS-CoV-2 using a molecular assay and reported to CDC by public health laboratories and a subset of clinical and commercial laboratories in the United States are summarized below. All laboratories are performing primary diagnostic functions; therefore, the percentage of specimens testing positive across laboratory types can be used to monitor overall trends in COVID-19 activity. As the outbreak progresses, it is possible that different types of laboratories will take on different roles, and the data interpretation may need to change. The lower percentage of specimens testing positive in clinical laboratories compared to public health and commercial laboratories may be influenced by COVID-19 activity in areas with reporting laboratories and by larger proportions of specimens obtained from children tested in these laboratories.
Summary of Laboratory Testing Results Reported to CDC*
Summary of Laboratory Testing Week 21 Cumulative since
Results Reported to the CDC (May 24–May 30, 2020) March 1, 2020
No. of specimens tested 1,054,626 10,337,330
Public Health Laboratories 175,585 1,426,171
Clinical Laboratories 88,660 922,190
Commercial Laboratories 790,381 7,988,969
No. of positive specimens 62,403 (5.9%) 1,239,169 (12.0%)
Public Health Laboratories 10,529 (6.0%) 163,645 (11.5%)
Clinical Laboratories 5,206 (5.9%) 75,477 (8.2%)
Commercial Laboratories 46,668 (5.9%) 1,000,047 (12.5%)
* Commercial and clinical laboratory data represents select laboratories and does not capture all tests performed in the United States.
Additional virologic surveillance information:
https://www.cdc.gov/flu/weekly/overview.htm#anchor_1539281228772* Commercial laboratories began testing for SARS-CoV-2 in early March, but the number and geographic distribution of reporting commercial laboratories became stable enough to calculate a weekly percentage of specimens testing positive as of March 29, 2020.
VIEW DATA TABLESPublic Health Laboratorieshttps://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/05292020/images/public-health-lab.gifClinical Laboratorieshttps://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/05292020/images/clinical-labs.gifCommercial Laboratorieshttps://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/05292020/images/commercial-lab.gifOutpatient/Emergency Department IllnessTwo syndromic surveillance systems are being used to monitor trends in outpatient and emergency department visits that may be associated with COVID-19 illness. Each system monitors a slightly different syndrome, and together these systems provide a more comprehensive picture of mild to moderate COVID-19 illness than either would individually. Both systems are currently being affected by recent changes in healthcare seeking behavior, including increased use of telemedicine, compliance with recommendations to limit emergency department (ED) visits to severe illnesses, and increased practice of social distancing. These changes affect the numbers of people seeking care in the outpatient and ED settings and their reasons for doing so.
ILINetThe U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) provides data on visits for influenza-like illness (ILI) (fever [≥100○F] and cough and/or sore throat) to approximately 2,600 primary care providers, emergency departments and urgent care centers in all 50 states, Puerto Rico, the District of Columbia and the U.S. Virgin Islands. Mild COVID-19 illness presents with symptoms similar to ILI, so ILINet is being used to track trends of mild to moderate COVID-19 illness and allows for comparison with prior influenza seasons.
Nationwide during week 22, 0.9% of patient visits reported through ILINet were due to ILI. This percentage is well below the national baseline of 2.4% and represents the tenth week of decline after three weeks of increase beginning in early March. The percentage of visits for ILI in week 22 remains low among all age groups. Nationally, laboratory-confirmed influenza activity as reported by clinical laboratories is at levels usually seen during summer months which, along with changes in healthcare seeking behavior and the impact of social distancing, is likely contributing to the low level of ILI activity.
VIEW GRAPH IMAGEhttps://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/05292020/images/percent-ili-visits.gif* Age-group specific percentages should not be compared to the national baseline.
On a regional level, the percentage of outpatient visits for ILI ranged from 0.5% to 1.3% during week 22. All ten regions are at low levels and below their region-specific baselines.
Note: In response to the COVID-19 pandemic, new sites will be enrolled in ILINet throughout the summer. This will result in an increase in patient visits and the percentage of visits for ILI may change in comparison to previous weeks. During week 21, new sites were added in Regions 1, 4, and 6. While these regions remain below baseline levels for ILI, these system changes should be kept in mind when drawing conclusions from these data. Any changes in ILI due to changes in respiratory virus circulation will be highlighted here.
Overall Percentage of Visits for ILI Link https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/05292020/percent-ili-visits.htmlAge Group ILI Data Linkhttps://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/05292020/percent-ili-visits-age.htmlILI Activity LevelsData collected in ILINet are used to produce a measure of ILI activity for all 50 states, Puerto Rico, the District of Columbia and New York City. The mean reported percentage of visits due to ILI for the current week is compared to the mean reported during non-influenza weeks, and the activity levels correspond to the number of standard deviations below, at or above the mean.
The number of jurisdictions at each activity level during week 22 and the change compared to the previous week are summarized in the table below and shown in the following maps. The decreasing percentage of visits for ILI described above are reflected in this week’s ILI activity levels.
Number of Jurisdictions Compared to
Activity Level Week 22 Previous Week
(Week Ending May 30, 2020)
Very High 0 No change
High 0 -1
Moderate 1 -1
Low 1 -1
Minimal 51 +2
Insufficient Data* 1 -1
*Data collected in ILINet may disproportionally represent certain populations within a state, and may not accurately depict the full picture of influenza activity for the whole state. Differences in the data presented here by CDC and independently by some state health departments likely represent differing levels of data completeness with data presented by the state likely being the more complete.
National Syndromic Surveillance Program (NSSP): Emergency Department (ED) VisitsNSSP is a collaboration among CDC, federal partners, local and state health departments and academic and private sector partners to collect, analyze and share electronic patient encounter data received from multiple healthcare settings. To track trends of potential COVID-19 visits, visits for COVID-19-like illness (CLI) (fever and cough or shortness of breath or difficulty breathing or presence of a coronavirus diagnosis code) and ILI to a subset of emergency departments in 47 states are being monitored.
Nationwide during week 22, 1.8% of emergency department visits captured in NSSP were due to CLI and 0.6% were due to ILI. This is the tenth week of decline in the percentage of visits for ILI and the eighth week of declining percentage of visits for CLI. Compared to week 21, all 10 HHS regionsexternal icon had declining percentages of visits for CLI during week 22; all 10 regions also had declining or stable percentages of visits for ILI.
Additional information about medically attended outpatient and emergency department visits for ILI and CLI: Surveillance Methodshttps://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/purpose-methods.html#outpatientHospitalizationsThe COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) conducts population-based surveillance for laboratory-confirmed COVID-19-associated hospitalizations in select counties participating in the Emerging Infections Program (EIP) and the Influenza Hospitalization Surveillance Project (IHSP).
A total of 26,623 laboratory-confirmed COVID-19-associated hospitalizations were reported by sites between March 1, 2020, and May 30, 2020. The overall cumulative hospitalization rate was 82.0 per 100,000 population. Among the 0-4 years, 5-17 years, 18-49 years, 50-64 years, and ≥ 65 years age groups, the highest rate of hospitalization is among adults aged ≥ 65 years (254.7 per 100,000), followed by adults aged 50-64 years (126.2 per 100,000) and adults aged 18-49 years (46.7 per 100,000).
VIEW GRAPH IMAGEhttps://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/05292020/images/lab-confirmed-hospitalizations.gifWithin the 18-49 years and ≥ 65 years age groups, the hospitalization rates increased with increasing age.
Age Group Cumulative Rate per 100,000 Population
Overall 82.0
0-4 years 4.9
5-17 years 2.4
18-49 years 46.7
18-29 years 23.7
30-39 years 46.2
40-49 years 77.1
50-64 years 126.2
65+ years 254.7
65-74 years 185.7
75-84 years 307.5
85+ years 470.6
Among the 0-4 years and 5-17 years age groups, there appears to be a slight upward trend in weekly hospitalization rates, though these rates are limited by smaller case counts and may change as additional data are received. Weekly rates in the 18-29 years age group have been holding steady, while weekly rates have been declining in all other age groups.
Among the 26,623 laboratory-confirmed COVID-19-associated hospitalized cases, 21,282 (79.9%) had information available on race and ethnicity while collection of race and ethnicity data was still pending for 5,341 (20.1%) cases. Of the 21,282 cases with race and ethnicity data, 35.5% were non-Hispanic White, 33.5% were non-Hispanic Black, 18.2% were Hispanic or Latino, 4.7% were non-Hispanic Asian or Pacific Islander, and 1.5% were non-Hispanic American Indian and or Alaska Native persons. Persons of multiple races represented 0.2% of cases, and 6.4% of cases had unknown race and ethnicity. In comparison, the COVID-NET catchment area population includes 58.8% non-Hispanic White, 17.7% non-Hispanic Black, 14.0% Hispanic or Latino, 8.8% non-Hispanic Asian or Pacific Islander, and 0.7% non-Hispanic American Indian or Alaska Native residents. Additional data on race and ethnicity are available.
COVID-19-associated hospitalization rates by race/ethnicity are calculated using hospitalized COVID-NET cases with known race and ethnicity for the numerator and NCHS bridged-race population estimates for the denominator. Rates are adjusted to account for differences in age distributions within race/ethnicity strata in the COVID-NET catchment area; the age strata used for the adjustment include 0-17, 18-49, 50-64, 65-74, 75-84, and ≥ 85 years. Age-adjusted hospitalization rates are highest among non-Hispanic American Indian or Alaska Native and non-Hispanic Black persons, followed by Hispanic or Latino persons. Non-Hispanic American Indian or Alaska Native persons have a rate approximately 5 times that of non-Hispanic White persons, non-Hispanic Black persons have a rate approximately 4.5 times that of non-Hispanic White persons, while Hispanics or Latinos persons have a rate approximately 3.5 times that of non-Hispanic White persons.
VIEW GRAPH IMAGEhttps://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/05292020/images/lab-confirmed-hospitalizations-underlying.gifAmong 6,000 hospitalized adults with information on underlying medical conditions, 91.6% had at least one reported underlying medical condition. The most commonly reported were hypertension, obesity, chronic metabolic disease, and cardiovascular disease.
Additional data on demographics, signs and symptoms at admission, underlying conditions, interventions, outcomes, and discharge diagnoses, stratified by age, sex, and race and ethnicity, are available.
Additional hospitalization surveillance information:
Surveillance Methodshttps://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/purpose-methods.html#hospitalizationAdditional rate datahttps://gis.cdc.gov/grasp/COVIDNet/COVID19_3.htmlAdditional demographic and clinical datahttps://gis.cdc.gov/grasp/COVIDNet/COVID19_5.htmlMortality SurveillanceThe National Center for Health Statistics (NCHS) collects death certificate data from vital statistics offices for all deaths occurring in the United States. Based on death certificate data available on June 4, 2020, 8.4% of all deaths occurring during the week ending May 30, 2020 (week 22) were due to pneumonia, influenza or COVID-19 (PIC). This is the sixth week of a declining percentage of deaths due to PIC; however, the percentage remains above the epidemic threshold of 6.3% for week 22. Data for recent weeks are incomplete, and the PIC percentage may increase as more death certificates representing deaths during these weeks are processed.
Weekly mortality surveillance data include a combination of machine coded and manually coded causes of death collected from death certificates. Percentages of deaths due to PIC are higher among manually coded records than more rapidly available machine coded records. Due to the additional time needed for manual coding, the initially reported PIC percentages may be lower than percentages calculated from final data.
Additional NCHS mortality surveillance information:Surveillance Methodshttps://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/purpose-methods.html#mortalityProvisional Death Counts for COVID-19https://www.cdc.gov/nchs/nvss/vsrr/COVID19/index.htmProvisional Death Counts for PIChttps://www.cdc.gov/nchs/data/health_policy/Provisional-Death-Counts-COVID-19-Pneumonia-and-Influenza.pdfPage Last Reviewed: June 5, 2020
Content source: National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases
*( Page 1 of 1 )*
